Last reviewed · How we verify
CHF1535 pMDI — Competitive Intelligence Brief
phase 2
Corticosteroid
Respiratory
Small molecule
Live · refreshed every 30 min
Target snapshot
CHF1535 pMDI (CHF1535 pMDI) — Chiesi Farmaceutici S.p.A.. CHF1535 pMDI is a corticosteroid inhalation powder.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CHF1535 pMDI TARGET | CHF1535 pMDI | Chiesi Farmaceutici S.p.A. | phase 2 | Corticosteroid | ||
| Emflaza | DEFLAZACORT | Ptc Therap | marketed | Corticosteroid [EPC] | 2017-01-01 | |
| Fluocinolone Acetonide | FLUOCINOLONE | Eurofarma | marketed | Corticosteroid [EPC] | 2016-01-01 | |
| Arnuity Ellipta | FLUTICASONE FUROATE | Haleon Us Holdings | marketed | Corticosteroid | Glucocorticoid receptor | 2007-01-01 |
| Lotemax | LOTEPREDNOL ETABONATE | Bausch Health | marketed | Corticosteroid | Glucocorticoid receptor | 1998-01-01 |
| Pandel | HYDROCORTISONE PROBUTATE | ANI Pharmaceuticals | marketed | Corticosteroid | Glucocorticoid receptor | 1997-01-01 |
| Flonase | fluticasone propionate | GSK (GlaxoSmithKline) | marketed | Inhaled/intranasal corticosteroid | Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor | 1994-11-04 |
Recent regulatory actions (last 90 days)
- — Flonase · FDA · approved · US · GSK (GlaxoSmithKline)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Flonase · 7500444*PED · Compound · US
- — Flonase · 10195375 · Formulation · US
- — Flonase · 12083270 · Method of Use · US
- — Flonase · 10195375*PED · Compound · US
- — Lotemax · 11219597 · Method of Use · US
- — Lotemax · 11596599 · Method of Use · US
- — Lotemax · 10857096 · Method of Use · US
- — Lotemax · 10864219 · Method of Use · US
- — Lotemax · 10945948 · Method of Use · US
- — Lotemax · 10940108 · Method of Use · US
- — Lotemax · 9737491 · Method of Use · US
- — Lotemax · 9827191 · Formulation · US
- — Lotemax · 10993908 · Method of Use · US
- — Lotemax · 12115246 · Formulation · US
- — Lotemax · 10688045 · Formulation · US
- — Lotemax · 11642317 · Formulation · US
- — Lotemax · 10646437 · Formulation · US
- — Lotemax · 9393213 · Formulation · US
- — Lotemax · 10646436 · Formulation · US
- — Lotemax · 11872318 · Formulation · US
- — Lotemax · 9056057 · Formulation · US
- — Lotemax · 9532955 · Method of Use · US
- — Lotemax · 10058511 · Formulation · US
- — Lotemax · 11219596 · Method of Use · US
- — Flonase · 10918816 · Formulation · US
- — Lotemax · 11534395 · Formulation · US
- — Flonase · 11554229 · Method of Use · US
- — Flonase · 10918816*PED · Compound · US
- — Lotemax · 10596107 · Formulation · US
- — Flonase · 11969544 · Formulation · US
Sponsor landscape (Corticosteroid class)
- · 22 drugs in this class
- Pfizer · 9 drugs in this class
- Chiesi Farmaceutici S.p.A. · 6 drugs in this class
- Assistance Publique - Hôpitaux de Paris · 6 drugs in this class
- Merck & Co. · 5 drugs in this class
- LEO Pharma · 4 drugs in this class
- Allergan · 4 drugs in this class
- AbbVie · 4 drugs in this class
- Bristol-Myers Squibb · 3 drugs in this class
- Bausch Health · 3 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CHF1535 pMDI CI watch — RSS
- CHF1535 pMDI CI watch — Atom
- CHF1535 pMDI CI watch — JSON
- CHF1535 pMDI alone — RSS
- Whole Corticosteroid class — RSS
Cite this brief
Drug Landscape (2026). CHF1535 pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/chf1535-pmdi. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab